Laboratory Profiles of Nasopharyngeal Carcinoma Patients
- DOI
- 10.2991/ahsr.k.220206.072How to use a DOI?
- Keywords
- Nasopharyngeal Carcinoma; Laboratory Profiles; Prognosis; Predictors
- Abstract
Nasopharyngeal Carcinoma (NPC) is one of the most common head and neck malignant neoplasms worldwide. Laboratory profile is rarely evaluated in Indonesia as a prognostic consideration. The aim of this research is to describe the laboratory profile of NPC patients. This is descriptive research using a total sampling method from 2016-to 2020. The general characteristics and laboratory profiles are collected from Nasopharyngeal Cancer Registry. The data collected will be presented in tables as frequency and percentages. More than half of the participants were male (68.27%), aged more than 45 years old (65.38%). The majority of the subjects reported a KPS of more than 80 (84.94%). Most of the participants showed WHO type III (47.57%). Bone (42.22%) was the most common metastases site. Normal hemoglobin (57.14%), leukocyte (57.99%), thrombocyte (91.36%), ALP (81.82%), AST (89.66%), ALT (61.26%), direct bilirubin (76.00%), indirect bilirubin (63.30%), total bilirubin (86.60%) and urea (84.10%) levels were found in most of our subjects. Calcium <8.6 mg/dL (92.21%) and creatinine >1.5 mg/dL (69.2%) were observed in most cases. This study indicated a worse prognosis by anemia, leukocytosis, and a high De Ritis ratio. In comparison, a better prognosis is predicted by low ALP levels, high calcium, direct bilirubin, and total bilirubin. In addition, pretreatment laboratory profiles should be assessed to predict the prognosis of patients with NPC.
- Copyright
- © 2022 The Authors. Published by Atlantis Press International B.V.
- Open Access
- This is an open access article under the CC BY-NC license.
Cite this article
TY - CONF AU - Nur Akbar Aroeman AU - Ifiq Budiyan Nazar AU - Yussy Afriani Dewi PY - 2022 DA - 2022/02/21 TI - Laboratory Profiles of Nasopharyngeal Carcinoma Patients BT - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021) PB - Atlantis Press SP - 390 EP - 396 SN - 2468-5739 UR - https://doi.org/10.2991/ahsr.k.220206.072 DO - 10.2991/ahsr.k.220206.072 ID - Aroeman2022 ER -